What:  Luncheon with the Experts presented by the Carcinoid Cancer Foundation

Who:
Satya (Nanu) Das, MD, MSCI, is the featured guest

When:  Thursday, January 27, 2022 from 12 noon to 1 pm, Eastern Time
Click on the orange date above to add the event to your calendar.
Where:  CCF’s Facebook Page, https://www.facebook.com/Carcinoid/. Just come to the page at noon and the program will begin. There is no need to register nor is there a special link.
For anyone not on Facebook, each of the presentations in the series is available on CCF’s YouTube channel, https://www.youtube.com/user/CarcinoidNETs. To receive notifications of all new videos on our YouTube channel, CLICK LIKE, SUBSCRIBE and HIT THE BELL to receive notifications each time a new video is uploaded.
Satya (Nanu) Das, MD, MSCI, is a medical oncologist and hematologist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. He is the lead of the NET program at VICC and is the medical oncology lead for the peptide receptor radionuclide therapy program. His research interests center on gastrointestinal cancer, with a focus on NETs and drug development. He is the principal investigator of several clinical trials in NETs.
Among Dr. Das’s research projects is designing studies for patients with NETs and NECs, utilizing the impairment of DNA damage repair to create new treatment strategies for gastrointestinal cancers and assessing when to optimally sequence PRRT. Clinically, Dr. Das takes care of patients with advanced GI malignancies with a specific interest in those with neuroendocrine tumors and colorectal, pancreatic, and gastric adenocarcinoma. NET patients make up more than 60% of Dr. Das’s practice.
Dr. Das is a co-author on a just-published article in JAMA Open Network, “External Validation of a Clinical Score for Patients with Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.” This article reports on a Clinical Score (CS), which is the initial prognostic score to help NET patients with well-differentiated neuroendocrine tumors to estimate the benefit from peptide receptor radionuclide therapy, PRRT.
powered by emma
Subscribe to our email list.